B
BioSerenity
Leading global providers of remote diagnostic solutions
About BioSerenity
BioSerenity is a global startup operating in the healthcare technology sector, specifically focusing on sleep research and electroencephalogram (EEG) devices. Their primary offerings include a fully customizable software for managing sleep and EEG labs, and a range of innovative, connected medical devices designed to make EEGs more accessible.
Read full description
Their software solution includes features for scheduling, home sleep test (HST) processing, and shipping, making it a comprehensive tool for labs. Their EEG devices, including their featured product, the ICECap, are designed for easy use and quick setup, making brainwave acquisition more efficient and user-friendly.
In addition to their products, BioSerenity also offers their vast real-world database for device and algorithm development, providing a valuable resource for researchers and developers in the field.
The company's business model revolves around selling their software and devices to sleep and EEG labs, hospitals, and research institutions. They also generate revenue by providing access to their database and conducting sleep-focused research studies through their BioSerenity Research Group.
In summary, BioSerenity is a tech startup providing innovative solutions for sleep research and EEG labs, with a business model based on product sales, data access, and research services.
At a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- Paris, France
- Employees
- 273
- Open positions
- 17
- Dealroom signal
- 73.2/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices, Health Platform
- Sector
- Biotech & Life Sciences, Biotechnology, Neurology, Remote Monitoring
- Technology
- Artificial Intelligence, Hardware, Deep Tech, Connected Device, IoT InternetOfThings
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Apr 2024
- Capital deployed
- $7.7M
- Preferred round
- EARLY VC
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Nov 2023 | $26M | $358M | Jolt Capital | ↗ |
| FundingOther financing | Feb 2022 | $0 | — | SCOR | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for BioSerenity is 6.2K monthly website visits, down 1.6% over the last three months. BioSerenity's team grew 3.4% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Kurma Partners
Eurazeo
Series A3 investors entered at this stage
Bpifrance
LBO France
Dassault Systemes
Series B and later1 investor entered at this stage
Jolt Capital
Other known investors4 additional known investors
EIT Health
SCOR- PHPitié-Salpêtrière University Hospital
Sorbonne University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about BioSerenity on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BioSerenity’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.